A Clinical Trial to Evaluate the Effects of a Plant-Based Liquid Supplement on Metabolic Health and Overall Well-Being

June 23, 2026 updated by: Biocol Labs
This single-arm clinical trial will evaluate the effects of a plant-based liquid supplement on metabolic health, digestive health, skin health, and overall well-being. Twenty participants aged 40 to 60 years with elevated alanine transaminase (ALT) or aspartate transaminase (AST) levels will use the supplement daily for 90 days. Participants will complete questionnaires, provide body composition and waist circumference measurements, submit photographs, and undergo blood testing throughout the study. Outcomes include changes in metabolic biomarkers, body composition, digestive symptoms, skin health, and overall well-being.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Nevada
      • Las Vegas, Nevada, United States, 89118
        • Citruslabs

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age 40 to 60 years
  • Elevated ALT or AST identified during prescreening blood testing
  • Currently experiencing at least two of the following:

Stomach discomfort, Constipation, Diarrhea, Heartburn, Bloating, Gas, Abdominal pain, Skin redness or pimples, Sugar cravings

  • Willing to comply with study requirements
  • Willing to discontinue supplements or herbal remedies targeting detoxification, digestive health, liver function, or skin health during the study
  • Willing to avoid starting new products, medications, or supplements targeting detoxification, digestive health, liver function, or skin health
  • Willing to maintain normal diet, sleep patterns, and activity levels
  • Generally healthy without uncontrolled chronic disease
  • Resides in the United States
  • Not participating in another research study during the study period
  • Has access to a study partner to take study photographs

Exclusion Criteria:

  • Severe digestive disorders including acid reflux, IBS, IBD, Crohn's disease, or gastrointestinal tract surgeries
  • Liver disease
  • Known allergy or hypersensitivity to study product ingredients Chronic conditions that would interfere with study participation, including oncological or psychiatric disorders
  • Known severe allergic reactions
  • Pregnant, breastfeeding, or attempting to conceive
  • Unwilling to follow study procedures
  • Stopped hormonal birth control within the past month
  • History of substance abuse
  • Use of prescription diabetes medications, including GLP-1 receptor agonists such as Ozempic, Wegovy, or Mounjaro

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Plant-Based Liquid Supplement
Participants will consume one ampule of the study product diluted in approximately 8 ounces of water before the first meal of the day throughout the study period.
Dietary supplement: Plant-Based Liquid Supplement
A liquid dietary supplement containing choline bitartrate, zinc sulfate, manganese sulfate, artichoke leaf extract, fennel extract, rosemary leaf extract, L-arginine monohydrochloride, inositol, bromelain, papain, sorbitol, glycerin, artificial flavour, and potassium sorbate.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Body Weight
Time Frame: Baseline, Day 30, Day 60, and Day 90.
Change in body weight measured using a Withings smart scale.
Baseline, Day 30, Day 60, and Day 90.
Change in Waist Circumference
Time Frame: Baseline, Day 7, Day 30, Day 60, and Day 90.
Change in waist circumference measured using a tape measure and recorded in centimeters.
Baseline, Day 7, Day 30, Day 60, and Day 90.
Change in Body Fat Mass
Time Frame: Baseline, Day 7, Day 30, Day 60, and Day 90.
Change in body fat mass measured using a Withings smart scale.
Baseline, Day 7, Day 30, Day 60, and Day 90.
Change in Lean Body Mass
Time Frame: Baseline, Day 7, Day 30, Day 60, and Day 90.
Change in lean body mass measured using a Withings smart scale.
Baseline, Day 7, Day 30, Day 60, and Day 90.
Change in Visceral Fat Index
Time Frame: Baseline, Day 7, Day 30, Day 60, and Day 90.
Change in visceral fat index measured using a Withings smart scale.
Baseline, Day 7, Day 30, Day 60, and Day 90.
Change in Alanine Aminotransferase (ALT)
Time Frame: Baseline, Day 30, Day 60, and Day 90.
Change in serum alanine aminotransferase concentration measured by hepatic function panel.
Baseline, Day 30, Day 60, and Day 90.
Change in Aspartate Aminotransferase (AST)
Time Frame: Baseline, Day 30, Day 60, and Day 90
Change in serum aspartate aminotransferase concentration measured by hepatic function panel.
Baseline, Day 30, Day 60, and Day 90
Change in Alkaline Phosphatase (ALP)
Time Frame: Baseline, Day 30, Day 60, and Day 90.
Change in serum alkaline phosphatase concentration measured by hepatic function panel.
Baseline, Day 30, Day 60, and Day 90.
Change in Total Bilirubin
Time Frame: Baseline, Day 30, Day 60, and Day 90.
Change in serum total bilirubin concentration measured by hepatic function panel.
Baseline, Day 30, Day 60, and Day 90.
Change in Total Cholesterol
Time Frame: Baseline, Day 30, Day 60, and Day 90.
Change in serum total cholesterol concentration measured by lipid panel.
Baseline, Day 30, Day 60, and Day 90.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Participant-Reported Bloating Severity
Time Frame: Baseline, Day 1, Day 3, Day 7, Day 30, Day 60, and Day 90.
Change in participant-reported bloating severity assessed by study questionnaire.
Baseline, Day 1, Day 3, Day 7, Day 30, Day 60, and Day 90.
Change in Participant-Reported Flatulence Severity
Time Frame: Baseline, Day 1, Day 3, Day 7, Day 30, Day 60, and Day 90.
Change in participant-reported flatulence severity assessed by study questionnaire.
Baseline, Day 1, Day 3, Day 7, Day 30, Day 60, and Day 90.
Change in Participant-Reported Heartburn Severity
Time Frame: Baseline, Day 1, Day 3, Day 7, Day 30, Day 60, and Day 90.
Change in participant-reported heartburn severity assessed by study questionnaire.
Baseline, Day 1, Day 3, Day 7, Day 30, Day 60, and Day 90.
Change in Participant-Reported Digestive Comfort
Time Frame: Baseline, Day 1, Day 3, Day 7, Day 30, Day 60, and Day 90.
Change in participant-reported digestive comfort assessed by study questionnaire.
Baseline, Day 1, Day 3, Day 7, Day 30, Day 60, and Day 90.
Change in Participant-Reported Skin Health
Time Frame: Baseline, Day 1, Day 3, Day 7, Day 30, Day 60, and Day 90.
Change in participant-reported skin health assessed by study questionnaire.
Baseline, Day 1, Day 3, Day 7, Day 30, Day 60, and Day 90.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Biocol Labs

Collaborators

Citruslabs

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 5, 2025

Primary Completion (Actual)

January 15, 2026

Study Completion (Actual)

January 15, 2026

Study Registration Dates

First Submitted

June 23, 2026

First Submitted That Met QC Criteria

June 23, 2026

First Posted (Actual)

June 29, 2026

Study Record Updates

Last Update Posted (Actual)

June 29, 2026

Last Update Submitted That Met QC Criteria

June 23, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • #20758

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Metabolic Health

Clinical Trials on Plant-Based Liquid Supplement

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Brazil

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe